Publikace
- Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme2020 | Farmaceutická fakulta v Hradci Králové
- Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance2019 | Farmaceutická fakulta v Hradci Králové
- Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes2019 | Farmaceutická fakulta v Hradci Králové
- Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro2018 | Farmaceutická fakulta v Hradci Králové
- Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1)2013 | Farmaceutická fakulta v Hradci Králové
- Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo2023 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo2022 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy2022 | Farmaceutická fakulta v Hradci Králové
Loading network view...